retatrutide peptide clinical trial Results: 28.3% Weight Loss Data retatrutide clinical trial results weight

It has Phase 3 REDEFINE-1 data showing about 22.7% weight loss at 68 weeks, and an NDA was filed with FDA in December 2025

Pouran Faghri is an Adjunct Full Professor in the Department of Environmental Health Sciences at the Fielding School of Public Health, University of California, Los Angeles

Controlling the role of BPC 157 likely involves its particular interaction with the major systems involved in wound healing, such as the NO-system (counteracted harmful events, arising from either NO-blockade or NOS-substrate application) (Sikiric et al., 2014) and the prostaglandins system (i.e., large extent of the counteracted NSAIDs toxicity (Sikiric et al., 2013) as well as counteracted developing and already formed adjuvant arthritis in rats (Sikiric et al., 1997c))

All following steps were performed in low-binding tubes (Eppendorf)